AXITINIB

SynDRA canonical compound SYN0024934 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx
Primary target(s)	CSF1 \| CYP2C19 \| CYP3A5 \| FLT1 \| FLT4 \| KDR \| KIT \| PDGFRB \| PLK4
Mechanism of action	PDGFR tyrosine kinase receptor inhibitor \| VEGFR inhibitor
Indication	renal cell carcinoma (RCC)
Disease area	oncology

All known targets

inlyta
AG-013736
AG-13736
NSC-757441
Inlyta
AG013736
AG-013736, Axitinib
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
Axitinib (VEGFR inhibitor)
AG 013736
(E)-N-Methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide
C9LVQ0YUXG
NSC757441
NSC 757441
CHEBI:66910
(E)-N-methyl-2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-ylthio)benzamide
N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide
NCGC00241108-01
S1005
N-methyl-2-({3-[(E)-2-(pyridin-2-yl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide
N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)-BENZAMIDE
Axitinib [USAN]
CAS-319460-85-0
UNII-C9LVQ0YUXG
axitinibum
Axitinib [USAN:INN:JAN]
Axitinib (AG 013736)
4agc
BENZAMIDE, N-METHYL-2-((3-((1E)-2-(2-PYRIDINYL)ETHENYL)-1H-INDAZOL-6-YL)THIO)-
Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-
N-methyl-2-({3-[(1E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide
Inlyta (TN)
MFCD09837898
AG13736
4ag8
Axitinib (JAN/USAN)
AXITINIB [INN]